TSXV:BTI.H - Post by User
Comment by
prophetoffactzon Jan 25, 2023 9:25am
110 Views
Post# 35244769
RE:RE:Hey narmac
RE:RE:Hey narmac"We need a CEO with a vision, connections and negotiating skills."
Sounds like Rathjen.
She had the connections to Ladenberg Thalmann and got the ball rolling.
Her vision was as big as getting the Former Finance Director of Shire Pharmaceuticals to run the company. He defied anyone to find a company of Biodexa's size with more opportunity. It would no longer be just dependent on licensing but could develop xB3 therapeutics internally on its own. It had a lead glioblastoma drug and xB3 has an affiinity for gioblastoma. Biodexa could also create extended release drugs with Q-Sphera leap-frogging Denali, etc. The world's largest healthcare company is investigating Q-Sphera and xB3. No other company has developed extended release monoclonal antibodies like Q-Sphera, a key area for xB3. Biodexa also attracted a very strong and capable financial backer in Armistice Capital to provide a potential US$20 million cash runway to key hard data catalysts. The company would be listed on NASDAQ and have the scale to interest serious investors on the world stage. Rathjen has negotiated more and bigger deals, evaluations and potential transformative deals than any CEO in BTI's history(Chiesi, J&J, Daiichi, Ellipses, Neuramedy, Oxyrane, Aposense, Cresence, Biodexa).